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ABSTRACT
Diabetes mellitus is the most 
common medical complication 
of pregnancy and it carries a 
signiﬁcant risk to the foetus and 
the mother. Congenital malfor-
mations and perinatal morbidity 
remain common compared with 
the offspring of non diabetic preg-
nancies. Diabetic mothers are 
at risk of progression of micro-
vascular diabetic complications 
as well as early pregnancy loss, 
pre-eclampsia, polyhydramnios 
and premature labour. Glycaemic 
control before and during preg-
nancy is critical and the beneﬁt 
may result in a viable, healthy off-
spring. Gestational diabetes mel-
litus (GDM) which manifests for 
the ﬁrst time during pregnancy is 
common and on the increase, its 
proper management will reduce 
the risk of neonatal macrosomia 
and hypoglycaemia. Post-par-
tum evaluation of glucose toler-
ance and appropriate counselling 
in women with GDM may help 
decrease the high risk of subse-
quent type 2 diabetes in the long-
term. 
This article will brieﬂy review the 
changes in the carbohydrate me-
tabolism that characterise normal 
pregnancy and will focus on a 
practical approach to the care of 
patients with pre-existing diabe-
tes as well as GDM.
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INTRODUCTION
Diabetes mellitus is the most 
common medical complication of 
pregnancy. Gestational diabetes 
mellitus (GDM) represents ap-
proximately 90% of these cases 
and affects 2–5% of all pregnan-
cies and varies in direct propor-
tion to type 2 diabetes mellitus 
in the background population.[1] 
Pre-existing diabetes mellitus 
complicates 0.2% to 0.3% of preg-
nancies.[2] The importance of di-
abetes in pregnancy stems from 
the fact that it carries a signiﬁcant 
risk to both the foetus and the 
mother. Despite major advances 
in clinical management, we are 
still facing a higher incidence of 
malformations and perinatal mor-
bidity compared to the non-dia-
betic population. 
Over the past 30 years, great 
strides have been made in im-
proving the outcomes of women 
with type 1 diabetes who become 
pregnant. However, during the 
past decade, type 2 diabetes in 
pregnancy has emerged and is 
certain to become a prominent 
concern.[3] The St Vincent Dec-
laration, which has been adopt-
ed by most European countries, 
calls for (an outcome in diabetic 
pregnancy approximating the 
non-diabetic women).[4] Unfortu-
nately, pregnancy target has been 
achieved only in a few centres of 
excellence in Scandinavia and by 
the small intensive pre-concep-
tion control arm of the nine-year 
US Diabetes Control and Compli-
cations Trial.[5] 
Normal Glucose Regulation 
during Pregnancy: Metabolic 
changes occur in normal preg-
nancy in response to the increase 
in nutrient needs of the foetus 
and the mother. There are two 
main changes which are seen 
during pregnancy, progressive in-
sulin resistance that begins near 
mid-pregnancy and progresses 
through the third trimester to the 
level that approximates the insu-
lin resistance seen in individu-
als with type 2 diabetes mellitus. 
The insulin resistance appears to 
result from a combination of in-
creased maternal adiposity and 
the placental secretion of hor-
mones (progesterone, cortisol, 
placental lactogen, prolactin and 
growth hormone). The fact that 
insulin resistance rapidly abates 
following delivery suggests that 
the major contributors to this 
state of resistance are placental 
hormones. The second change is 
the compensatory increase in in-
sulin secretion by the pancreatic Libyan Journal of Medicine, Volume 1, 2006
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beta-cells to overcome the insu-
lin resistance of pregnancy. As a 
result, circulating glucose levels 
are kept within normal. If there 
is maternal defect in insulin se-
cretion and in glucose utilisation, 
then GDM will occur as the dia-
betogenic hormones rise to their 
peak levels.
Risks to the Foetus & the 
Neonate (Table 1 & 2): If the 
mother has hyperglycaemia, the 
foetus will be exposed to either 
sustained hyperglycaemia or in-
termittent pulses of hyperglycae-
mia; both situations prematurely 
stimulate foetal insulin secretion. 
Foetal hyperinsulinaemia may 
cause increased foetal body fat 
(macrosomia) resulting in difﬁcult 
delivery. It may also cause inhi-
bition of pulmonary maturation of 
surfactant resulting in respiratory 
distress of the neonate. 
The foetus may also have de-
creased potassium level caused 
by elevated insulin and glucose 
levels, and may therefore have 
cardiac arrhythmia. Foetal orga-
nogenesis is completed by seven 
weeks post-conception and there 
is an increased prev-
alence of congenital 
anomalies and spon-
taneous abortions in 
diabetic women with 
poor glycaemic con-
trol during this pe-
riod.[6] 
Because a woman 
may not even know 
she is pregnant at 
this time, it is imper-
ative that pre-preg-
nancy counselling 
and planning occur in 
women of child-bear-
ing age who have di-
abetes. It seems that 
post-prandial glucose levels are 
the most important determining 
factor on the subsequent risk of     www.ljm.org.ly   
page
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neonatal macrosomia. Pregnan-
cy in patients with diabetes is as-
sociated with a six-fold increase 
in perinatal mortality and a two-
fold increase in the rate of major 
congenital malformations and an 
eight fold increase in preterm de-
livery compared to the general 
population.[7-9] 
There is also an increase in neo-
natal hypoglycaemia which may 
cause permanent neurologic dam-
age, hyperbilirubinaemia, respi-
ratory distress and stillbirth. The 
associated increase of congeni-
tal anomalies for the foetus and 
spontaneous abortion in women 
with poor glycaemic control ap-
pears to be related to maternal 
glycaemic control rather than to 
the mode of anti-diabetic therapy 
during early pregnancy. 
The normalisation of maternal glu-
cose before and throughout preg-
nancy can decrease pregnancy-
related complications to those 
seen in non-diabetic 
pregnancies. Stud-
ies from many cen-
tres have shown that 
the higher the levels 
of glycosylated hae-
moglobin [HbA1c] in 
early pregnancy, the 
greater the incidence 
of anomalies and the 
higher the perinatal 
mortality. [7-9]
Risks to the mother (Table 3): 
Maternal diabetes complications 
are frequent in women with both 
type 1 and type 2 diabetes. Dia-
betic retinopathy and diabetic ne-
phropathy may progress or start 
de novo during the pregnancy.
Pre-eclampsia occurs in both type 
1 and type 2 diabetes mellitus and 
is high as it affects approximately 
20% of cases. [10] Other compli-
cations including polyhydramnios 
and worsening of chronic hyper-
tension are not uncommon. 
Management of Pregnancy in 
Women with Pre-existing Dia-
betes: Pre-pregnancy planning 
(Table 4) is essential to achieve a Libyan Journal of Medicine, Volume 1, 2006
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healthy baby and avoid maternal 
morbidity such as adverse preg-
nancy outcomes and progres-
sion of chronic diabetes compli-
cations. Ideally this is carried out 
by a team, which includes an ob-
stetrician and a diabetologist for 
optimum care. Clinical trials of 
pre-conception care to achieve 
stringent blood glucose control 
in the pre-conception period and 
during the ﬁrst trimester of preg-
nancy have demonstrated striking 
reductions in rates of malforma-
tion compared with infants of dia-
betic women who did not partici-
pate in pre-conception care.[11] 
Unfortunately, unplanned preg-
nancies occur in about two thirds 
of women with diabetes, preclud-
ing adequate pre-conception care 
and leading to persistent excess 
of malformations in their infants. 
To minimize the occurrence of 
these devastating malformations, 
standard care for all women with 
diabetes and of child-
bearing age should 
include. Counselling 
about the risk of mal-
formations associ-
ated with unplanned 
pregnancies and 
poor metabolic con-
trol and the use of ef-
fective contraception 
at all times unless 
the patient is in good 
metabolic control 
and actively trying to conceive.
Contraception for diabetic 
women: All forms of contracep-
tion carry some risk and every 
woman must be considered indi-
vidually. The combined oral con-
traceptive pill is effective if taken 
reliably, however, the ﬁrst gen-
eration, high dose oestrogen pills 
should be avoided as they may 
increase insulin requirement and 
increase the risk of vascular dis-
ease. The second and third gen-
eration pills have a much lower 
dose of oestrogen and can prob-
ably be used safely in the major-
ity of women with diabetes. The 
progesterone-only pill is reliable if 
taken regularly but omission may 
be more likely to result in preg-
nancy than with the combined pill.     www.ljm.org.ly   
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Injectable progestogens/implants 
are suitable for some patients. In-
tra-uterine contraceptive devices 
have the advantage of the lack of 
detrimental metabolic effect and 
the need for compliance; how-
ever, its failure rate is high. Other 
methods of contraception such 
as mechanical contraception can 
also be used in diabetic patients. 
Emergency contraception is safe 
for diabetic women and should be 
prescribed if needed.
Optimise glycaemic control: In 
preparation for pregnancy, oral 
hypoglycaemic agents should be 
discontinued and insulin started if 
needed, statins and ACE-inhibi-
tors should also be discontinued. 
Hypertension should be control-
led with safer drugs like Methyl-
dopa, Nifedipine or Labetalol. 
Diabetic complications should 
be assessed and treated. Regu-
lar self-monitoring should be en-
couraged to optimise control. 
Folic Acid should be started at 
least four weeks pre-conception. 
Glycaemic control should be op-
timised with the aim of pre-pran-
dial blood glucose < 5.5 mmol/l 
(<95mg/dl) and HbA1c < 7%. 
Diabetes ante-natal care: this 
should be provided in a special 
clinic and the team caring for 
pregnant women should ideally 
include a Diabetes Nurse Spe-
cialist, Dietician, Diabetologist 
and an Obstetrician. The aim of 
ante-natal care is to maintain tight 
glycaemic control and to monitor 
the mother for diabetes compli-
cations. Tighter glycaemic con-
trol has an impact on maternal 
and foetal complications, there-
fore, excellent glycaemic control 
should be continued throughout 
pregnancy, fasting blood glu-
cose should be kept < 5.5 mmol/l 
(<95mg/dl), post-prandial glucose 
< 7.8 mmol/l (<140 mg/dl) and 
HbA1c <7%. Tighter glycaemic 
control may lead to an increase 
in episodes of severe hypogly-
caemia and worsening of hy-
poglycaemia unawareness. The 
patient should be aware of subtle 
signs of hypoglycaemia, and the 
patient’s family should be taught 
the proper treatment of severe 
hypoglycaemia (i.e. Glucagon). 
Glucose monitoring: Home 
blood glucose monitoring is an 
essential part of maintaining eug-
lycaemic state and its goal is to 
detect glucose concentration to 
allow ﬁne-tuning of insulin adjust-
ment. Pre-prandial glucose level < 
5.5 mmol/l (<95mg/dl), and post-
prandial level glucose <7.8 mmol/
l (<140mg/dl). Post-prandial glu-
cose levels have been shown to Libyan Journal of Medicine, Volume 1, 2006
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correlate more with macrosomia 
than do fasting levels. Diabetes 
in early pregnancy studies found 
that third trimester post-prandial 
glucose levels were the strong-
est predictors of percentile birth 
weight.[12]
Dietary advice: The goal of diet in 
pregnancy is to provide adequate 
nutrition for the mother and the 
foetus, provide sufﬁcient calories 
for appropriate maternal weight 
gain, maintain normal glycaemia 
and avoid ketosis. Eating three 
small to moderate size meals and 
three snacks per day is appropri-
ate. Monitoring with a pre-break-
fast ketone measurement is rec-
ommended for patients who are 
on a hypo-caloric or carbohydrate 
restricted diet. 
Insulin therapy: Insulin regimes 
should be individualised but in 
type 1 patients multiple injection/
basal bolus regime of human in-
sulin is preferable and in type 2, 
twice-daily injections may be ap-
propriate. The aim is to achieve 
blood glucose as near normal as 
possible without excessive risk of 
hypoglycaemia. 
Hypoglycaemia: hypoglycaemia 
is common in pregnancy, particu-
larly in the ﬁrst trimester. Educa-
tion of patients and their families 
in the recognition and manage-
ment of hypoglycaemia is vital. A 
Glucagon kit should be provided 
early in pregnancy.
Ketoacidosis: Ketoacidosis is 
a preventable condition but po-
tentially lethal to the foetus at 
any stage of pregnancy. Women 
should be instructed to test their 
urine for ketones if their blood 
glucose readings are high or if 
they feel unwell. 
Retinopathy:  Diabetic retinopa-
thy may accelerate during preg-
nancy.[13] Fundoscopy is neces-
sary before conception and once 
in each trimester of pregnancy for 
all women with diabetes. 
Nephropathy: [13] Baseline as-
sessment of renal function by se-
rum creatinine and some measure 
of urinary protein excretion (urine 
albumin/creatinine ratio or 24-
hour albumin excretion) should 
be undertaken before conception. 
Women with microalbuminuria 
may experience transient wors-
ening during pregnancy; howev-
er, those with established neph-
ropathy with overt proteinuria are 
at increased risk of pre-eclamp-
sia and intra-uterine growth re-
tardation and premature delivery.     www.ljm.org.ly   
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Pregnancy may lead to perma-
nent worsening of renal function 
in more than 40% of those with 
serum creatinine of 250 umol/l or 
greater or creatinine clearance 
< 50ml/minute and therefore it 
should serve as a contraindica-
tion to pregnancy. However, at 
that level of impaired renal func-
tion fertility is reduced and preg-
nancy is rare. ACE-inhibitors for 
treatment of microalbuminuria 
should be discontinued in women 
who are attempting to become 
pregnant.
Hypertension: Hypertension is 
a frequent concomitant of diabe-
tes. Patients with type 1 diabetes 
frequently develop hypertension 
in association with diabetic ne-
phropathy, as manifested by the 
presence of overt proteinuria. Pa-
tients with type 2 diabetes more 
commonly have hypertension as a 
concomitant disease. In addition, 
pregnancy induced hypertension 
is a potential problem for women 
with diabetes. Hypertension con-
tributes to worsening of diabetic 
nephropathy and retinopathy in 
pregnancy. ACE-inhibitors, beta-
blockers and diuretics should be 
avoided in women contemplating 
pregnancy if they are being used 
for hypertension. Methyl-Dopa or 
Labetalol may be substituted.
Neuropathy: Compartment syn-
dromes such as carpal tunnel 
syndrome may be exacerbated by 
pregnancy and should be treated 
symptomatically with splints. Au-
tonomic neuropathy particularly 
manifested by gastroparesis, 
hypoglycaemia unawareness, 
or orthostatic hypertension may 
complicate the management of 
diabetes in pregnancy. These 
complications should be identi-
ﬁed, appropriately evaluated and 
treated before conception.
Cardiovascular disease: Un-
treated coronary artery disease 
is associated with a high mor-
tality rate during pregnancy and 
women with signiﬁcant coronary 
artery disease should be advised 
against pregnancy.
Foetal monitoring: The major 
risks for the foetus of a diabetic 
woman are congenital malforma-
tions, intra-uterine death, usually 
after 30 weeks and macrosomia, 
which may result in signiﬁcant 
problems in labour for both moth-
er and baby. Ante-natal foetal sur-
veillance must be planned so that 
each risk is addressed efﬁciently 
and in a timely manner. Ultra-
sound scanning must be available 
for assessing gestational age, ex-
amining for congenital abnormali-Libyan Journal of Medicine, Volume 1, 2006
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ties and monitoring foetal growth 
and liquor volume. All diabetic pa-
tients should be counselled about 
the possibility of a neural tube 
defect and offered serum alpha-
fetoprotein blood test between 
15 and 19 weeks gestation. A 
detailed ultrasound scan at be-
tween 20 and 22 weeks for care-
ful assessment of foetal anatomy 
is mandatory. The risk of intra-
uterine foetal death is increased 
by a factor of approximately three 
times, mostly conﬁned to the third 
trimester. Although strict control 
of maternal blood glucose levels 
will reduce this risk, but not as 
low as that of the general popu-
lation. Ultrasound assessment 
should be carried out at each visit 
from 26 weeks. The programme 
of surveillance must be modiﬁed 
if there are additional recognised 
risk factors, such as hyperten-
sion or renal disease. This may 
mean more frequent ultrasound 
assessment in addition to umbili-
cal artery Doppler measurement 
and cardio-tocography. Unlike in 
the non-diabetic, it is excessive 
foetal growth rather than retarded 
growth that may be associated 
with the greatest risk. Increasingly 
large abdominal circumference in 
relation to the bi-parietal diameter 
can be easily monitored by serial 
ultrasound scans and these two 
parameters should be measured 
and documented at each visit, in 
association with assessment of 
liquor volume.
Timing of delivery: Uncompli-
cated case with no evidence of 
foetal compromise, spontaneous 
delivery at term is standard prac-
tice. When there are maternal 
complications of diabetes, com-
plications of pregnancy, previous 
stillbirth or evidence of abnormal 
foetal growth, each case must be 
considered in its own merit with 
timely delivery in hospital. Deliv-
ery by elective Caesarean section 
should be considered if the ultra-
sound estimated foetal weight 
is > 4kg. A previous Caesarean 
section in a diabetic woman will 
usually be managed by a repeat 
Caesarean section. In the ab-
sence of these or other obstetric 
contra-indications a spontaneous 
vaginal delivery should be pos-
sible, with induction of labour as 
required. If delivery is indicated 
before 36 weeks then administra-
tion of a steroid to the mother for 
48 hours prior to delivery should 
be undertaken. Steroids will up-
set glycaemic control and should 
only be given on an inpatient ba-
sis with careful monitoring of the 
glucose level and appropriate al-
teration of the insulin regime.    www.ljm.org.ly   
page
37
Libyan Journal of Medicine, Volume 1, 2006
ljm
Management of labour and de-
livery:
1. Glucose control during labour. 
It is necessary to administer IV 
insulin and Dextrose to prevent 
ketoacidosis and to maintain the 
blood glucose as near normal 
as possible. The insulin require-
ments after delivery should return 
to about the pre-pregnancy level. 
Labour and delivery of women 
with diabetes should be under-
taken in units where there is neo-
natal care.
2. Neonatal problems. This would 
include hypoglycaemia, poly-
cythaemia, respiratory distress 
syndrome, jaundice, hypocalcae-
mia and hypomagnesemia. Rou-
tine blood glucose monitoring of 
the baby should be performed for 
the ﬁrst 12 hours. 
3. Post-natal care. Insulin re-
quirements fall dramatically at the 
time of delivery and insulin dose 
should be reduced to around the 
pre-pregnancy level. Breastfeed-
ing also reduces insulin require-
ments and appropriate reduction 
should therefore be made once 
feeding is established. It is usual-
ly possible to stop insulin in wom-
en with GDM and in women with 
type 2 diabetes mellitus who do 
not intend to breastfeed. Contra-
ception should be discussed whil 
the patient is in hospital. 
Gestational diabetes mellitus: 
GDM is deﬁned as a glucose intol-
erance that begins or 
is ﬁrst detected dur-
ing pregnancy. Dif-
ferences in screen-
ing programmes and 
diagnostic criteria 
make it difﬁcult to 
compare frequen-
cies of GDM among 
various populations. 
Nevertheless, ethnic-
ity has been proven 
to be an independent 
risk factor for GDM, which varies 
in prevalence in direct propor-
tion to the prevalence of Type 2 
diabetes in a given population or 
ethnic group. 
The prevalence may range from 1 Libyan Journal of Medicine, Volume 1, 2006
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- 14% of all pregnancies, depend-
ing on the population sample, 
with 2 - 5% being the most com-
mon rate.[1] GDM develops when 
a woman is unable to secrete suf-
ﬁcient insulin to compensate for 
the increased insulin resistance 
during pregnancy. The foetus re-
sponds to hyperglycaemia by se-
creting large quantities of insulin. 
The result is increasing adiposity 
and the accrual of visceral fat. 
Women who develop GDM are at 
increased risk for type 2 diabetes 
mellitus.[14] The screening and 
diagnostic methods for GDM re-
main controversial, especially the 
threshold values for the diagno-
sis. [15] 
Data from the Hyperglycaemia 
and Adverse Pregnancy Outcome 
(HAPO) study, correlating blood 
glucose levels with outcomes will 
hopefully lead to common agree-
ment on the value for the diagno-
sis in future.[16] Screening meth-
ods for GDM vary from presence 
of maternal risk factors (table 5) to 
biochemical screening with 50gm 
OGTT (1hr blood glucose > 7.8 
mmol/l (>140 mg/dl); 
screening based on 
maternal risk factors 
is more cost effec-
tive.[15] 
Several European 
centres support a glu-
cose load of 75 gm 
for diagnosis performed between 
weeks 24 and 28 of gestation 
as recommended by the World 
Health Organization and the Dia-
betes Pregnancy Study Group of 
the European Association for the 
Study of Diabetes.[17] 
Management of GDM: Treatment 
of GDM can substantially reduce 
perinatal morbidity (table 6) from 
4% to 1%.[18, 19] Women diag-
nosed with GDM should receive 
dietary advice and calorie intake 
should be reduced if overweight. 
Such measures will achieve met-
abolic control in the majority of 
women. They should monitor their 
own blood glucose levels and, if 
the pre-prandial glucose levels 
are consistently above 5.5mmol/l 
(95 mg/dl), insulin should be com-
menced with the aim of keeping     www.ljm.org.ly   
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pre-prandial blood glucose be-
low 5.5 mmol/l (95 mg/dl), and 
two hour post-prandial below 7.8 
mmol/l (140 mg/dl). 
There is limited data on the safety 
and efﬁcacy of Glibenclamide or 
Metformin in GDM. [20, 21, 22] A 
75g oral Glucose Tolerance Test 
should be performed 6 weeks or 
more after delivery and the results 
interpreted by revised WHO crite-
ria. (Table 7) Women with a his-
tory of GDM should be screened 
for GDM during any future preg-
nancy. They should be advised to 
make life style changes to reduce 
their risk of subsequent type 2 
diabetes mellitus.[14] For further 
reading, readers are advised to 
refer to the Report of the Expert 
Committee on the diagnosis and 
classiﬁcation of Diabetes Melli-
tus. [23]  
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